{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:01:33Z","timestamp":1773158493331,"version":"3.50.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>The advent of therapeutic antibodies, or biological medications, has transformed the treatment of many inflammatory diseases in dermatology. Recently, the development of biosimilars, biological drugs that are highly similar in quality, safety and efficacy to approved biologics, has changed this landscape. Although biosimilars are not identical to their reference product, they are required to have the same mechanism of action, route of administration, dosage form and strength as the reference product. This also leads to the possibility that subtle differences in the activity of these biosimilars can lead to differing clinical responses. We report the first case of a lichenoid eruption induced by a biosimilar to infliximab after switching from infliximab. Several days after initial infusion of the biosimilar, the patient developed a pruritic papulosquamous eruption that was biopsied to reveal a lichenoid drug eruption. Possible mechanisms for lichenoid drug eruptions as a result of tumour necrosis factor-\u03b1 inhibitor administration are discussed, along with reasons why such a reaction may occur with a biosimilar but not the original, reference product. This case report calls attention to the unique differences between biosimilars and biological medications that a clinician should consider prior to prescribing these medications.<\/jats:p>","DOI":"10.1111\/bjd.15686","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T13:44:06Z","timestamp":1496151846000},"page":"965-968","source":"Crossref","is-referenced-by-count":12,"title":["A dissimilar biosimilar? Lichenoid drug eruption induced by an infliximab biosimilar"],"prefix":"10.1093","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7972-2302","authenticated-orcid":false,"given":"N.","family":"Gonzalez","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, Dermatology 1425 Madison Avenue, Box 1047 New York NY 10029-6574 U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Patel","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine Department of Medicine Division of Dermatology Montefiore Medical Center 1300 Morris Park Avenue Bronx NY 10461 U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Han","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, Dermatology 1425 Madison Avenue, Box 1047 New York NY 10029-6574 U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,4,1]]},"reference":[{"key":"2023011316193637100_bjd15686-bib-0001","volume-title":"Information on biosimilars","author":"U.S. Food and Drug Administration"},{"key":"2023011316193637100_bjd15686-bib-0002","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2008.09.032","article-title":"Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists","volume":"61","author":"Asarch","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2023011316193637100_bjd15686-bib-0003","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","article-title":"A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy","volume":"76","author":"Choe","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023011316193637100_bjd15686-bib-0004","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","article-title":"Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study","volume":"76","author":"Park","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023011316193637100_bjd15686-bib-0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12026-016-8843-5","article-title":"Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study","volume":"65","author":"Benucci","year":"2017","journal-title":"Immunol Res"},{"key":"2023011316193637100_bjd15686-bib-0006","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","article-title":"Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study","volume":"76","author":"Yoo","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023011316193637100_bjd15686-bib-0007","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3109\/14397595.2015.1022297","article-title":"Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis","volume":"25","author":"Takeuchi","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2023011316193637100_bjd15686-bib-0008","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/14397595.2016.1206244","article-title":"Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab","volume":"27","author":"Tanaka","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2023011316193637100_bjd15686-bib-0009","first-page":"297","article-title":"Switching from Remicade\u00ae to Remsima\u00ae is safe and feasible: a prospective, open-label study","volume":"11","author":"Buer","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2023011316193637100_bjd15686-bib-0010","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/jgh.12997","article-title":"Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study","volume":"30","author":"Jung","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"2023011316193637100_bjd15686-bib-0011","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2133.2005.06999.x","article-title":"Lichen planus is associated with human herpesvirus type 7 replication and infiltration of plasmacytoid dendritic cells","volume":"154","author":"De Vries","year":"2006","journal-title":"Br J Dermatol"},{"key":"2023011316193637100_bjd15686-bib-0012","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1600-0560.2006.00527.x","article-title":"Type I interferon-associated cytotoxic inflammation in lichen planus","volume":"33","author":"Wenzel","year":"2006","journal-title":"J Cutan Pathol"},{"key":"2023011316193637100_bjd15686-bib-0013","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/000155599750010418","article-title":"Lichen planus induced by interferon-alpha-2B therapy in a patient with cutaneous malignant melanoma","volume":"79","author":"Herrera Saval","year":"1999","journal-title":"Acta Derm Venereol"},{"key":"2023011316193637100_bjd15686-bib-0014","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1080\/14712598.2017.1238454","article-title":"The design of clinical trials to support the switching and alternation of biosimilars","volume":"16","author":"Faccin","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"2023011316193637100_bjd15686-bib-0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/1753-0407.12241","article-title":"Hypersensitivity reaction to a biosimilar insulin glargine","volume":"7","author":"Garcia-Nares","year":"2015","journal-title":"J Diabetes"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.15686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.15686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.15686","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/178\/4\/965\/47588036\/bjd0965.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/178\/4\/965\/47588036\/bjd0965.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:27:48Z","timestamp":1676384868000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/178\/4\/965\/6602525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,1]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,1]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.15686","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2018,4,1]]},"published":{"date-parts":[[2018,4,1]]}}}